Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
Managing multiple myeloma (MM) patients receiving advanced (four or more) lines of treatment is a complex challenge. Therefore, real-world data are essential to better understand and address the medical need of this challenging population. We used the EMMY cohort, a French longitudinal real-world study, to describe the characteristics and outcomes of 2127 MM patients receiving advanced-line treatments between 2017 and 2020. A wide variety of treatments were used without a predominant combination showing an evolution over time. Patients exhibited median time to next treatment and overall survival ranging from 7.8 months (95% CI: 6.7-7.8) and 19.4 months (95% CI: 17.4-22.5) in Line 4 (L4) to 4.8 months (95% CI: 3.5-6) and 12.6 months (95% CI: 8.7-16.6) in L8, respectively. The EMMY study provides valuable insights into the real-world application of advanced-line treatments, demonstrating rapid disease progression and poor outcomes in these patients before the novel anti-B-cell maturation antigen (BCMA) directed therapies. These findings highlight the critical need for novel therapies in this population.
Authors
- Hélène Demarquette
- Ronan Garlantézec (ORCID: https://orcid.org/0000-0001-7420-6341)
- Lionel Karlin (ORCID: https://orcid.org/0000-0002-1185-4488)
- Benoit Bareau
- Titouan Cazaubiel (ORCID: https://orcid.org/0009-0007-5834-5318)
- Caroline Jacquet
- Abdelaziz Chaib
- Cécile Sonntag (ORCID: https://orcid.org/0009-0001-1616-2501)
- Cyrille Touzeau (ORCID: https://orcid.org/0000-0003-0275-2575)
- Arthur Bobin (ORCID: https://orcid.org/0000-0002-8416-391X)
- Pascale Olivier (ORCID: https://orcid.org/0000-0002-1801-9581)
- Stéphane Darre
- Clémence Santana (ORCID: https://orcid.org/0009-0002-5618-8471)
- Laure Vincent (ORCID: https://orcid.org/0000-0001-5904-1286)
- Margaret Macro
- Thomas Chalopin (ORCID: https://orcid.org/0000-0002-9833-3115)
- Bruno Royer (ORCID: https://orcid.org/0000-0002-8649-7008)
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Sophie Rigaudeau (ORCID: https://orcid.org/0000-0002-9639-9305)
- Karim Belhadj‐Merzoug
- Laurent Frenzel (ORCID: https://orcid.org/0000-0002-6085-2163)
- Mohamad Mohty (ORCID: https://orcid.org/0000-0001-8536-7781)
- Denis Caillot
- Cyrille Hulin
- Jean Eudes Fontan
Institutions
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Université de Poitiers (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Bretonneau (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Intercommunal Aix-Pertuis (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Laboratoire National de Référence (MA)
- Hôpital Lyon Sud (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hôpital André Mignot (FR)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Hôpital Privé Jean Mermo (FR)
- Centre Hospitalier de Valence (FR)
- Centre Hospitalier d'Arras (FR)
- Hôpital Saint Eloi (FR)
- Hôpital Saint-Louis (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Hôpital d'Hautepierre (FR)
- Hôpital Civil, Strasbourg (FR)
- Microenvironment and B-cells: Immunopathology, Cell, Differentiation and Cancer (FR)
Publication Details
- Journal
- Clinical Hematology International
- Published
- 2025-09-18
- DOI
- https://doi.org/10.46989/001c.143641
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00